The acquisition includes the purchase of certain assets from Bako Diagnostics, a national provider of specialty laboratory testing services, and the acquisition of StrataDx, which is recognized for its advanced diagnostics in dermatopathology. The completion of these transactions is anticipated to significantly bolster Fulgent's operational execution and strategic outlook in the healthcare market.
As part of the acquisition process, Fulgent has also entered into an Assignment and Assumption of Lease for a commercial property in Alpharetta, Georgia, which will support its expanded operations. The lease agreement, effective March 17, 2026, involves approximately 29,099 square feet of laboratory and office space, further solidifying Fulgent's infrastructure to support its growth.
Fulgent's management expressed confidence that these acquisitions will not only enhance their service capabilities but also provide a competitive edge in the rapidly evolving healthcare landscape. The company aims to leverage the expertise of both Bako Diagnostics and StrataDx to improve patient outcomes and drive innovation in diagnostic testing.
This acquisition aligns with Fulgent's long-term strategy to transform from a diagnostic-focused business into a fully integrated precision medicine company, enhancing its portfolio and expanding its market presence. The company is committed to delivering high-quality laboratory services and advancing its therapeutic development initiatives, which are crucial for addressing a broad range of healthcare needs.
